Genesee Capital Advisors’s Eli Lilly LLY Stock Holding History

Genesee Capital Advisors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$282K	Hold	244	–	–	0.09%	137
2026 Q2	$292K	Sell	244 -12	-5%	-$12.3K	0.09%	133
2026 Q1	$235K	Sell	256 -1	-0.4%	-$1.01K	0.1%	120
2025 Q4	$277K	Sell	257 -148	-37%	-$142K	0.11%	106
2025 Q3	$309K	Buy	405 +1	+0.2%	+$744	0.13%	94
2025 Q2	$315K	Hold	404	–	–	0.14%	97
2025 Q1	$334K	Buy	404 +1	+0.2%	+$832	0.17%	97
2024 Q4	$311K	Hold	403	–	–	0.14%	101
2024 Q3	$357K	Sell	403 -26	-6%	-$23.4K	0.17%	89
2024 Q2	$389K	Hold	429	–	–	0.19%	82
2024 Q1	$334K	Buy	429 +1	+0.2%	+$712	0.18%	82
2023 Q4	$250K	Buy	+428	New	+$250K	0.15%	89

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $104B AUM 51.65% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Genesee Capital Advisors's LLY Position: Q3 2026 in Review

Genesee Capital Advisors held its Eli Lilly (LLY) position steady in Q3 2026 at 244 shares worth $282K. The position accounts for 0.09% of the portfolio, ranked #137.

Genesee Capital Advisors first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. The position peaked at $389K in Q2 2024. 3,244 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

Genesee Capital Advisors held 244 shares of Eli Lilly worth $282K as of Q3 2026.
Genesee Capital Advisors left its Eli Lilly share count unchanged in Q3 2026.
Eli Lilly made up 0.09% of Genesee Capital Advisors's portfolio in Q3 2026, its #137 holding.
Genesee Capital Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
Genesee Capital Advisors's Eli Lilly position peaked at $389K in Q2 2024.
3,244 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Genesee Capital Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.